Bacteriophage as effective decolonising agent for elimination of MRSA from anterior nares of BALB/c mice

BMC Microbiology

Volumn 14, Issue 1, 2014, Pages

  Chhibber, Sanjay ^a   Gupta, Paridhi ^a   Kaur, Sandeep ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Adherence; Invasion; Nasal colonisation; Nasal epithelial cells; S. aureus

Indexed keywords

PSEUDOMONIC ACID; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIOPHAGE; BACTERIUM ADHERENCE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; EX VIVO STUDY; FEMALE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; MUTANT; NONHUMAN; NOSE MUCOSA; ANIMAL; BIOLOGICAL THERAPY; CELL SURVIVAL; ENDOCYTOSIS; EPITHELIUM CELL; GROWTH, DEVELOPMENT AND AGING; HETEROZYGOTE; MICROBIOLOGY; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS PHAGE; TREATMENT OUTCOME; VIROLOGY;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BIOLOGICAL THERAPY; CARRIER STATE; CELL SURVIVAL; COMBINED MODALITY THERAPY; ENDOCYTOSIS; EPITHELIAL CELLS; FEMALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE, INBRED BALB C; MUPIROCIN; NASAL MUCOSA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS PHAGES; TREATMENT OUTCOME;

EID: 84908054695     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/s12866-014-0212-8     Document Type: Article

References (57)

1. Boyce JM, Landry M, Deetz TR, DuPont HL: Epidemiologic studies of an outbreak of nosocomial methicillin-resistant S. aureus infections. Infect Control 1981, 2: 110-116.
2. Kluytmans J, Von Belkum A, Verburgh H: Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997, 10: 505-520.
3. von Eiff C, Becker K, Machka K, Stammer H, Peters G: Hospital and community-acquired methicillin-resistant Staphylococcus aureus in Germany. Clin Microbiol Infect 2006, 12 (Suppl 4):461.
4. Weems JJ, Beck LB: Nasal carriage of Staphylococcus aureus as a risk factor for skin and soft tissue infections. Current Infectious Disease Reports 2002, 4 (5):420-425.
5. Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ: Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009, 48: 922-930.
6. Doebbeling BN, Reagan DR, Pfaller MA, Houston AK, Hollis RJ, Wenzel RP: Long-term efficacy of intranasal mupirocin ointment. A prospective cohort study of Staphylococcus aureus carriage. Arch Intern Med 1994, 54: 1505-1508.
7. Fernandez C, Gaspar C, Torrellas A, Vindel A, Saez-Nieto JA, Cruzet F, Aguilar L: A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995, 35: 399-408.
8. Wills QF, Kerrigan C, Soothill JS: Experimental bacteriophage protection against Staphylococcus aureus abscesses in a rabbit model. Antimicrob Agents Chemother 2005, 49: 1220-1221.
9. Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D: Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 2007, 51: 2765-2773.
10. Sunagar R, Patil SA, Chandrakanth RK: Bacteriophage therapy for Staphylococcus aureus bacteremia in streptozotocin-induced diabetic mice. Research in Microbiol 2010, 161 (10):854-860.
11. Hsieh SE, Lo HH, Chen ST, Lee MC, Tseng YH: Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2. Appl Environ Microbiol 2011, 77 (3):756-761.
12. VinodKumar CS, Srinivasa H, Basavarajappa KG, Patil U, Bandekar N, Patil R: Abrogation of Staphylococcus aureus wound infection by bacteriophage in diabetic rats. Int J Pharm Sci and Drug Res 2011, 3 (3):202-207.
13. Chhibber S, Kaur T, Kaur S: Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. Plos One 2013, 8 (2):e65022.
14. Bedi MS, Verma V, Chhibber S: Amoxicillin and specific bacteriophage can be used together for eradication of biofilm of Klebsiella pneumoniae B5055. World J Microbiol Biotechnol 2009, 25: 1145-1151.
15. th edition M7-A9. : Clinical and Laboratory Standards Institute; 2012.
16. - secretion in nasal epithelia of CF mice. Am J Physiol 1994, 266: 1478-1483.
17. Adherence, invasion and cytotoxicity of some bacterial pathogens. GS El-Housseiny, MM Aboulwafa, NA Hassouna, J of Am Sci 2010 6 10 260 268
18. Saliba AM, Filloux A, Ball G, Silva ASV, Assis MC, Plotkowski MC: Type III secretion-mediated killing of endothelial cells by Pseudomonas aeruginosa. Microbial Pathogenesis 2002, 33 (4):153-166.
19. O'Neill AJ, Cove JH, Chopra I: Mutation frequencies for resistance to fusidic acid and rifampicin in Staphylococcus aureus. J Antimicrob Chemother 2001, 47: 647-650.
20. Kaur S, Chhibber S, Harjai K: Methicillin-resistant Staphylococcus aureus phage plaque size enhancement using sub-lethal concentrations of antibiotics. Appl Environ Microbiol 2012, 78: 8227-8233.
21. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Laichalk LL, McGillicuddy DC, Standiford TJ: Neutralization of macrophage inflammatory protein-2 attenuates neutrophil recruitment and bacterial clearance in murine Klebsiella pnenumonia. J Infect Dis 1996, 173: 159-165.
22. Histopathological evaluation of scalds and contact burns in the pig model. TA Brans, RP Dutrieux, MJ Hoekstra, RW Kreis, JS Du Pont, Burns 1994 20 548 551
23. Mupirocin in General Practice: a placebo controlled trial. JC Gould, JH Smith, H Moncur, International Congress and Symposium Series. Number 80. Mupirocin, A Novel Topical Antibiotic Royal Society of Medicine, London, Wilkinson DS, Price JD, 1984 85 93
24. Coia JE, Duckworth GJ, Edwards DI, Farrington M, Fry C, Humphreys H, Mallaghan C, Tucker DR: Guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006, 63 (Suppl 1):S1-S44.
25. Fujimura S, Watanabe A: Survey of high- and low-level mupirocin-resistant strains of methicillin-resistant Staphylococcus aureus in 15 Japanese hospitals. Chemotherapy 2003, 49: 36-38.
26. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA: Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 2003, 24: 342-346.
27. Jones JC, Rogers TJ, Brookmeyer P, Dunne WM Jr, Storch GA, Coopersmith CM, Fraser VJ, Warren DK: Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007, 45: 541-547.
28. Simor AE, Tammy L, Stuart TL, Louie L, Watt C, Marianne Ofner-Agostini M, Denise Gravel D, Michael Mulvey M, Loeb M, McGeer A, Bryce E, Matlow A: Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007, 51: 3880-3886.
29. Aly R, Shinefield HR, Litz C, Maibach HI: Role of teichoic acid in the binding of Staphylococcus aureus to nasal epithelial cells. J Infect Dis 1980, 141: 463-465.
30. MSCRAMM-mediated adherence of microorganisms to host tissues. JM Patti, BL Allen, MJ McGavin, M Hook, Annu Rev Microbiol 1994 48 585 617 10.1146/annurev.mi.48.100194.003101 7826020
31. O'Brien LM, Walsh EJ, Massey RC, Peacock SJ, Foster TJ: Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol 2002, 4: 759-770.
32. Roche FM, Meehan M, Foster TJ: The Staphylococcus aureus surface protein SasG and its homologues promote bacterial adherence to human desquamated nasal epithelial cells. Microbiology 2003, 149: 2759-2767.
33. Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, Gross M, Nicholson G, Neumeister B, Mond JJ, Peschel A: Role of techoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004, 10: 243-245.
34. Wertheim HF, Vos MC, Boelens HA, Voss A, Vandenbroucke-Grauls CM, Meester MH, Kluytmans JA, van Keulen PH, Verbrugh HA: Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. J Hosp Infect 2004, 56: 321-325.
35. Coates T, Bax R, Coates A: Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother 2009, 64: 9-15.
36. Dziewanowska K, Patti JM, Deobald CF, Bayles KW, Trumble WR, Bohach GA: Fibronectin binding protein and host cell tyrosine kinase are required for internalization of Staphylococcus aureus by epithelial cells. Infect Immun 1999, 67: 4673-4678.
37. Jevon M, Guo C, Ma B, Mordan N, Nair SP, Harris M, Henderson B, Bentley G, Meghji S: Mechanisms of internalization of Staphylococcus aureus by cultured human osteoblasts. Infect Immun 1999, 67: 2677-2681.
38. Lammers A, Nuijten PJM, Smith HE: The fibronectin binding proteins of Staphylococcus aureus are required for adhesion to and invasion of bovine mammary gland cells. FEMS Microbiol Lett 1999, 180: 103-109.
39. Staphylococcal fibronectin binding protein interacts with heat shock protein 60 and integrins: role in internalization by epithelial cells. K Dziewanowska, AR Carson, JM Patti, CF Deobald, KW Bayles, GA Bohach, Infect Immun 2000 68 6321 6328 10.1128/IAI.68.11.6321-6328.2000 11035741
40. Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. EH Alexander, MC Hudson, Appl Microbiol Biotechnol 2001 56 361 366 10.1007/s002530100703 11549002
41. Massey RC, Kantzanou MN, Fowler T, Day NP, Schofield K, Wann ER, Berendt AR, Hook M, Peacock SJ: Fibronectin-binding protein A of Staphylococcus aureus has multiple, substituting, binding regions that mediate adherence to fibronectin and invasion of endothelial cells. Cell Microbiol 2001, 3: 839-851.
42. Lowy FD: Is Staphylococcus aureus an intracellular pathogen? Trends Microbiol 2000, 8: 341-343.
43. Sachse F, Becker K, von Eiff C, Metze D, Rudack C: Staphylococcus aureus invades the epithelium in nasal polyposis and induces IL-6 in nasal epithelial cells in vitro. Allergy 2010, 65 (11):1430-1437.
44. Clement S, Vaudaux P, Francois P, Schrenzel J, Huggler E, Kampf S, Chaponnier C, Lew D, Lacroix JS: Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinositis. J Infect Dis 2005, 192: 1023-1028.
45. Sinha B, Francois PP, Nusse O, Foti M, Hartford OM, Vaudaux F, Foster TJ, Lew DF, Herrmann M, Krause KH: Fibronectin-binding protein acts as Staphylococcus aureus invasin via fibronectin bridging to integrin alpha5beta1. Cell Microbiol 1999, 1: 101-118.
46. Cellular invasion by Staphylococcus aureus involves a fibronectin bridge between the bacterial fibronectin-binding MSCRAMMs and host cell beta1 integrins. T Fowler, ER Wann, D Joh, S Johansson, TJ Foster, M Hook, Eur J Cell Biol 2000 79 672 679 10.1078/0171-9335-00104 11089915
47. Agerer F, Michel A, Ohlsen K, Hauck CR: Integrin-mediated invasion of Staphylococcus aureus into human cells requires Src family protein-tyrosine kinases. J Biol Chem 2003, 278: 42524-42531.
48. Fowler T, Johansson S, Wary KK, Hook M: Src kinase has a central role in in vitro cellular internalization of Staphylococcus aureus. Cell Microbiol 2003, 5: 417-426.
49. http://scholarcommons.usf.edu/etd/2485 Clem: Bacteriophage for the elimination of methicillin-resistant Staphylococcus aureus (MRSA) colonization and infection. : Graduate School Theses and Dissertations;.
50. Analysis of antibiotic resistance regions in Gram-negative bacteria. SR Partridge, FEMS Microbiol Reviews 2011 35 820 855 10.1111/j.1574-6976.2011.00277.x
51. k eliminates Staphylococcus aureus in the nares of mice. Bioengineered Bugs 2010, 1: 404-407.
52. A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent anti-staphylococcal protein. VD Paul, SS Rajagopalan, S Sundarrajan, SE George, JY Asrani, R Pillai, R Chikkamadaiah, M Durgaiah, B Sriram, S Padmanabhan, BMC Microbiol 2011 11 226 10.1186/1471-2180-11-226 21985151
53. Phage therapy: past history and future prospects. RM Carlton, Arch Immun Ther Exp 1999 47 267 274
54. Bacteriophages as therapeutic agents. A Sulakvelidze, JG Morris, Ann Med 2001 33 507 509 10.3109/07853890108995959 11730156
55. Ritz HL, Kirkland JJ, Bond GG, Warner EK, Petty GP: Association of high levels of serum antibody to staphylococcal toxic shock antigen with nasal carriage of toxic shock antigen producing strains of Staphylococcus aureus. Infect Immun 1984, 43: 954-958.
56. Human nasal respiratory secretions and host defense. MA Kaliner, Am Rev Respir Dis 1991 144 52 S56 1892328
57. Rigby KM, DeLeo FR: Neutrophils in innate host defense against Staphylococcus aureus infections. Semin Immunopath 2012, 34 (2):237-259.